Custom Peptide Modifications: What to Specify in Your RFQ

01

Define the modified structure—not only the modification name

Terms such as biotinylated, fluorescent or PEG-modified are incomplete without position and linkage. The same label can describe multiple structures with different synthesis, purification and analytical implications.

Write the full sequence, the modified residue or terminal position, the linker where applicable and the required terminal groups. A structure drawing or annotated sequence should be attached when nomenclature could be ambiguous.

• Full sequence and direction
• N- and C-terminal configuration
• Exact modification and position
• Linker identity and length
• Counterion or salt requirement if relevant
• Required form after purification

02

State terminal acetylation and amidation explicitly

N-terminal acetylation and C-terminal amidation are common requests, but they should never be assumed. A sequence written without terminal notation can be interpreted as a free amine and free acid.

Include both terminal states even when only one end is modified. This provides an unambiguous structure for quotation, production and mass calculation.

03

Define biotin and PEG-linker configuration

Biotin can be placed at a terminus or an internal residue and may be introduced directly or through a spacer. The spacer can affect accessibility in the intended research workflow, so the RFQ should not collapse biotin and linker into one generic option.

Published biotinylation methods and biotin-PEG work illustrate that labeling strategy and spacer design are part of the structure. Buyers should provide the intended configuration; the manufacturer should confirm feasibility and the expected analytical interpretation.

04

Identify fluorescent labels completely

A color name is not enough. State the exact fluorophore, attachment position and linker, and discuss light sensitivity or special handling if relevant to the selected label.

Fluorescent labels can alter hydrophobicity, chromatographic behavior and observed mass. The purification and analytical plan should therefore address the final labeled peptide rather than relying on data from the unlabeled precursor.

05

Treat phosphorylation, lipidation and other side-chain work as route decisions

Phosphorylation, fatty-acid attachment and other side-chain modifications can affect coupling strategy, solubility, purification and stability. State the modified residue and structural detail, not only the class of modification.

For multiple modifications, provide a single controlled structure. The feasibility review should examine whether the proposed combination is compatible with synthesis, deprotection, cleavage and purification.

06

Describe disulfides, cyclization and conjugation endpoints

For disulfide-containing peptides, identify the intended cysteine pairing. For cyclized structures, specify the bond or cyclization mode. For carrier or other conjugation projects, define whether the RFQ covers the peptide precursor, the activated intermediate or the final conjugate.

These distinctions affect what will be delivered and which analytical result can reasonably support it. If the conjugation step is outside the manufacturer scope, the reactive handle and protection state should be made explicit.

07

Recalculate the analytical expectations

A modification changes expected molecular mass and may change retention, ionization or detector response. The analytical record should correspond to the final requested structure and the agreed method.

Mass spectrometry can support identity-related assessment, while HPLC provides a chromatographic purity result under stated conditions. Neither output should be represented as answering every quality question.

• Expected molecular formula or mass where appropriate
• HPLC method and target criterion
• Mass-spectrometric output required
• Any modification-specific characterization
• Sample identity and batch linkage

08

Ask for feasibility before locking price and lead time

Modified projects should be technically reviewed before a final commitment. The review may identify a more practical linker, attachment point, scale or purity target, but any proposed change should be approved by the buyer before production.

A complete RFQ allows Stablize Peptides to assess the project without publishing confidential sequences. Detailed capabilities and the final route are provided in direct response to the inquiry.

RELATED GUIDANCE

Continue the procurement review